Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721709 | 1.00 | CES2 (0.52) | CES2PTPN5TSHRMAPK1AR | |
| SCHEMBL24793381 | 0.80 | CES2 (0.52) | CES2PTPN5TSHRMAPK1ALDH1A1 | |
| SCHEMBL6061078 | 0.79 | CES2 (0.56) | CES2PTPN5TSHRMAPK1AR | |
| SCHEMBL21303633 | 0.78 | CES2 (0.50) | CES2PTPN5TSHRMAPK1AR | |
| SCHEMBL28676412 | 0.77 | TSHR (0.56) | CES2PTPN5TSHRMAPK1AR | |
| SCHEMBL30417923 | 0.75 | CES2 (0.52) | CES2PTPN5TSHRAR | |
| SCHEMBL29708357 | 0.75 | IDO1 (0.47) | TSHRAR | |
| SCHEMBL2699647 | 0.75 | CES2 (0.52) | CES2PTPN5TSHRAR | |
| SCHEMBL695658 | 0.75 | IDO1 (0.47) | TSHRAR | |
| SCHEMBL28250189 | 0.75 | CES2 (0.52) | CES2PTPN5TSHRMAPK1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858952-B2 | Compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210347790-A1 | COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | LG CHEM, LTD. (KR) | 2021-11-11 | — | — | US | disclosed |
| US-20210119210-A1 | LITHIUM/SULFUR BATTERY WITH INCREASED CAPACITY AND ASSOCIATED PROCESSES | ARKEMA FRANCE (FR) | 2021-04-22 | — | — | US | disclosed |
| EP-3666779-A1 | ORGANIC ELECTROLUMINESCENT DEVICES COMPRISING HOST COMPOUNDS | cynora GmbH (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3640999-A1 | ORGANIC ELECTROLUMINESCENT DEVICE EMITTING BLUE LIGHT | cynora GmbH (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2019162332-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2009046371-A1 | METHODS OF TREATING METABOLIC DISEASES | METABOLEX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046371-A1 | METHODS OF TREATING METABOLIC DISEASES | METABOLEX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1716116-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080340-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | GPR119, SLC5A1, AADAC | CES2 382/4885PTPN5 537/4885TSHR 258/4885 |
| US-20210347790-A1 | COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | BLVRB, CDYL, CRY1 | CES2 344/4885PTPN5 2229/4885TSHR 3893/4885 |
| US-11858952-B2 | Compound and color conversion film comprising same | BLVRB, CDYL, CRY1 | CES2 344/4885PTPN5 2229/4885TSHR 3893/4885 |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | SLC5A1, GPR119, SLC5A2 | CES2 509/4885PTPN5 431/4885TSHR 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.